Introduction
Iron is an essential micronutrient involved in cellular energy and metabolism of both haematopoietic and extra-haematopoietic tissues, being critical for maintaining body homoeostasis. 1 -3 Cells with high-energy demand (hepatocytes, skeletal and cardiac myocytes, and renal cells) are particularly sensitive to iron depletion. 1 -3 Several cardiovascular disorders may be complicated by iron deficiency (ID), including subjects at high cardiovascular risk without overt heart disease, 4 diabetic patients with stable coronary artery disease (CAD) 5 and those with stable heart failure (HF), regardless of ejection fraction. 6 -9 Abnormal energy metabolism occurs in HF, 10, 11 and ID, additionally impeding energy metabolism, aggravates symptoms and worsens outcomes in these patients. 6 -9 An episode of acute heart failure (AHF) critically deranges haemodynamic and metabolic homoeostasis, and being a state of cardiovascular stress is likely to expose impaired efficiency of energy production. 12 Detrimental consequences of ID may be highlighted in this setting, but iron status in AHF has not been investigated so far.
Physiologically, we can distinguish two major iron pools in the body: stored iron (in hepatocytes, bone marrow sideroblasts, and reticuloendothelial cells) and utilized iron (circulating iron bound mainly to transferrin and intracellular iron in virtually all haematopoietic and extrahaematopoietic cells). 13, 14 In the physiological context, the description of iron status should include the insight into both pools, as they closely interact with each other and iron can be transferred between these compartments. 3, 13, 14 The diagnosis of ID should include concomitant depleted iron stores and iron avidity by metabolizing cells. Until now, an approach to ID diagnosis has traditionally been based on the assessment of low transferrin saturation (Tsat) and reduced serum ferritin. Unfortunately, these standard measures of iron status are unreliable in the acute clinical settings (AHF). 3 Serum ferritin reflects body iron stores, but either inflammation or oxidative stress may artificially increase its concentrations, regardless of actual iron status. 15, 16 Catabolism and malnutrition may lower serum transferrin disproportionate to serum iron, leading to artificial Tsat elevations. 15, 16 There are pathophysiological premises that circulating hepcidin and soluble transferrin receptor (sTfR) could be more sensitive alternatives in acute clinical settings for ID diagnosis. Hepcidin is secreted by hepatocytes and orchestrates systemic iron metabolism. 14, 17, 18 Whereas increased serum hepcidin may be due to either inflammation or/and excessive iron stores, low-circulating hepcidin reflects specifically depleted body iron stores with or without concomitant anaemia; the lower the hepcidin the more profoundly depleted iron stores. 14, 17, 18 Patients with stable systolic HF develop ID accompanied by low-serum hepcidin, which is not associated with either anaemia or inflammation, and in the setting of HF, circulating low hepcidin is a specific measure of depleted iron stores. 6 Soluble transferrin receptor is the shed fragment of a transmembrane receptor for iron-transferrin complex, the main mechanism for importing iron into all living cells, but especially the erythron. 14, 19, 20 Depleted utilized iron results in an increased cellular avidity for iron and increases the TfR expression (which is later shed to circulation) in order to facilitate intracellular iron influx. High-circulating sTfR reflects insufficient cellular iron amount, which is available for metabolic needs of both haematopoietic and extra-haematopoietic cells. 14, 19, 20 The aim of this study was to (i) propose a new definition of ID based on low-serum hepcidin and high-serum sTfR in patients hospitalized for AHF, (ii) assess the prevalence of ID and establish clinical factors associated with ID in an examined cohort of patients, and (iii) investigate the impact of ID on 12-month mortality in these patients.
Methods
Patients with acute heart failure The recruitment phase of the study was conducted among patients hospitalized for AHF in two cardiology centres in Poland (Wroclaw and Inowrocław). The criteria for patients to be included in the study were (i) age ≥18 years and (ii) a diagnosis of AHF as the primary cause of hospitalization. Exclusion criteria included (i) any treatment for anaemia and/ or ID in the previous 12 months and (ii) acute coronary syndrome as the direct cause of AHF.
Acute heart failure was diagnosed when there was a rapid onset/ change in signs or/and symptoms of HF (peripheral oedema, pulmonary congestion, and dyspnoea) associated with myocardial dysfunction (confirmed by echocardiography or/and elevated plasma NT-proBNP), which required specific treatment (i.e. loop diuretic or/and nitroglycerine or/ and inotropic agent) during hospitalization. 39 The study protocol was approved by the local ethics committee, and all subjects gave written informed consent. The study was conducted in accordance with the Declaration of Helsinki.
Haematological, iron, and other laboratory measurements in peripheral blood
In all patients, venous blood samples were taken at the emergency department on admission or in the intensive care unit during first hour after hospital admission. Laboratory measurements were made in fresh venous blood with EDTA or clotted blood. After centrifuging, the plasma and serum were collected and frozen at 2708C until further laboratory analyses.
Serum hepcidin (ng/mL) was measured using a commercially available enzyme-linked immunosorbent assay (ELISA) (BACHEM) (Cat. No. S-1337 detecting human hepcidin-25). This ELISA method was validated with a gold standard for hepcidin assessment, liquid chromatography mass spectrometry (LC MS) developed at King's College London, confirming a strong correlation between the measurements performed using the LC MS and the BACHEM assay in patients with chronic kidney disease (CKD) and healthy subjects. 21 Serum sTfR (mg/L) was measured using immunonephelometry (Siemens Healthcare Diagnostics, Inc., Deerfield, IL, USA). Iron deficiency was defined as a concomitance of depleted body iron stores (demonstrated as low-serum hepcidin) and insufficient iron amount in metabolizing cells (demonstrated as high-serum sTfR). The rigorous cut-off values for low-serum hepcidin and high-serum sTfR were derived from the normal values of healthy subjects (an age-and gender-matched control group published previously 6 ). Depleted body iron stores were diagnosed, when serum hepcidin was ,14.5 ng/mL (i.e. the 5th percentile among healthy controls). Insufficient intracellular iron amount in metabolizing cells (iron avidity) was diagnosed, when serum sTfR was ≥1.59 mg/L (i.e. the 95th percentile among healthy controls). As the consequence based on serum levels of hepcidin and sTfR, four groups of patients were distinguished: (i) subjects with the most profound ID-with both low hepcidin and high sTfR (as defined above), (ii) subjects with isolated low hepcidin, (iii) subjects with isolated high sTfR, and (iv) subjects with preserved iron status (neither low hepcidin nor high sTfR).
Additionally, the following standard blood biomarkers reflecting iron metabolism were measured directly: serum concentrations of ferritin (mg/L), iron (mg/dL), and total iron-binding capacity (TIBC, mg/dL). Tsat was calculated as the ratio of serum iron (mg/dL) and TIBC (mg/dL) multiplied by 100 and expressed as a percentage. Serum ferritin was measured using an immunoassay based on electrochemiluminescence with the Elecsys 2010 System (Roche Diagnostics GmbH, Mannheim, Germany). Serum iron and TIBC were assessed using a substrate method with Feren S (Thermo Fisher Scientific, Waltham, MA, USA). The definition of ID used in previous studies in patients with HF 3,8,22 -24 based on serum ferritin and Tsat (serum ferritin ,100 mg/L, or serum ferritin 100-299 mg/L with Tsat ,20%) was also applied in additional analyses. Haemoglobin concentration (g/dL)was measured using the ADVIA 120 automated system (Siemens, Healthcare Diagnostics, Deerfield, IL, USA). Anaemia was defined as haemoglobin ,12 g/dL in women and ,13 g/dL in men. 25 The plasma level of N-terminal pro-B type natriuretic peptide (NT-proBNP, pg/mL) was measured using an immunoassay based on electrochemiluminescence with the Elecsys 1010/2010 System (Roche Diagnostics GmbH, Mannheim, Germany). The serum level of interleukin 6 (IL-6, pg/mL) was measured using a commercially available ELISA (R&D Systems, Minneapolis, MN, USA). Estimated glomerular filtration rate (GFR, mL/min/1.73 m 2 ) was calculated using the Modification of Diet in Renal Disease equation. 26 
Study scheme and clinical follow-up
All the patients with AHF were regularly seen by the study investigators in outpatient HF clinics with follow-up ≥12 months in all survivors. Information regarding survival was obtained directly from patients or their relatives, from the HF clinic database or from the hospital system. No patient was lost to follow-up. The primary end-point was all-cause death. The length of follow-up of survivors and patients in whom an event occurred after 12 months was censored at 365 days.
We performed the power analysis of the study for the primary endpoint (all-cause deaths). For survival rates in two groups of 90 and 70%, for power of 0.85 and alpha 0.05, the number of required events and the numbers of patients together in two groups were 30 and 152, respectively.
Statistical analyses
Continuous variables with a normal distribution [age, systolic blood pressure (BP), heart rate, left ventricular ejection fraction (LVEF), sodium, GFR, albumins, uric acid, white blood cell (WBC) count, haemoglobin, Tsat] were expressed as means with standard deviations. The normality of the distributions of continuous variables was tested using the Kolmogorov-Smirnov test. The remaining continuous variables had a skewed distribution [(NT-proBNP, urea, aspartate transaminase (AST), alanine transaminase (ALT), g-glutamyltranspeptidase (GGTP), total bilirubin, C-reactive protein, IL-6, hepcidin, sTfR, ferritin], and were expressed as medians with upper and lower quartiles. For further analyses, these variables were log transformed in order to normalize their distribution. The categorical variables were expressed as numbers with percentages.
The statistical significance of differences between the groups was tested using either analysis of variance (ANOVA), Student's t-test, or the x 2 test, where appropriate. The associations between variables were assessed using the univariate Pearson's correlatory coefficients. The associations between ID, and clinical and laboratory variables were tested in patients with AHF using univariable and multivariable logistic regression models, where clinical variables were independent variables and ID was a dependent variable. The multivariable models included variables which were statistically significant associates in univariable models, and remained statistically significant also in a multivariable model.
To establish the effect of ID on survival, we performed Cox proportional hazard regression models, were ID (and other clinical variables) were predictors (determining variables), whereas the end-point was the length of follow-up with the information on clinical status at the end of follow-up (dead/alive), with the consideration that the follow-up of patients who survived 365 days and longer was censored at 365 days. The associations between iron status and survival were adjusted in multivariable models for subsequent variables which appeared to be statistically significant predictors in univariable models.
To estimate the ability of serum hepcidin alone, serum sTfR alone, and these two parameters combined together to predict death at 12 months, Iron deficiency in acute heart failure receiver operator characteristic curve analysis was performed with a calculation of areas under curve (AUC) using an algorithm of Gonen and Heller for Cox proportional hazard regression models. 27 To estimate the effect of the most profound ID (both low hepcidin and high sTfR), isolated low hepcidin and isolated high sTfR on 12-month mortality rates in patients with AHF, Kaplan-Meier curves for cumulative survival were constructed. Differences in survival rates were tested with the Cox-Mantel log-rank test.
All tests were two-sided. A value of P , 0.05 was considered statistically significant. All statistical analyses were performed using Statistica 10.
Results
Baseline characteristics of 165 examined patients with AHF are shown in Table 1 Prevalence of iron status abnormalities in patients with acute heart failure Low-serum hepcidin (regardless of serum sTfR) was found in 46% of patients with AHF (vs. 5% in controls, P , 0.001), whereas highserum sTfR (regardless of serum hepcidin)-in 66% of subjects. Iron deficiency (defined as both low hepcidin and high sTfR) was demonstrated in 61 (37%) of patients with AHF, whereas isolated high sTfR and isolated low hepcidin were found in 48 (29%) and 15 (9%) of subjects, respectively. Iron deficiency defined based on serum ferritin and Tsat was found in 107 (65%) patients with AHF. Parameters of iron status fulfilled the criteria of both definitions of ID (based on serum ferritin and Tsat, and based on serum hepcidin and sTfR) in 51 (31%) of subjects, whereas 48 (29%) of patients did not fulfil the criteria of any of these definitions. Ten (6%) patients with AHF had only ID diagnosed using serum hepcidin and sTfR, whereas 56 (34%) patients with AHF had only a diagnosis of ID based on serum ferritin and Tsat.
Among patients with AHF, serum hepcidin was not related to haemoglobin, and was only moderately at the most associated with serum sTfR (r ¼ 20.35, P , 0.001), Tsat (r ¼ 0.26, P , 0.01), and serum ferritin (r ¼ 0.49, P , 0.001). Serum sTfR was inversely weakly related to haemoglobin (r ¼ 20.36, P , 0.001), Tsat (r ¼ 20.38, P , 0.001), and serum ferritin (r ¼ 20.32, P , 0.001). Iron status parameters in four groups of patients with AHF distinguished based on serum hepcidin and sTfR were shown in Table 2 .
Associations between iron status and clinical variables in patients with acute heart failure
Patients with AHF and ID (both low hepcidin and high sTfR) when compared with the other subgroups of patients with AHF were characterized by: higher prevalence of peripheral oedema, more common previous history of HF, higher prevalence of diabetes mellitus, higher NT-proBNP, urea and uric acid, and lower sodium, albumin, and haemoglobin (all P , 0.05 in univariable models, Table 1 ).
There were no associations between serum hepcidin and liver function tests (AST, ALT, GGPT, total bilirubin, and albumins, all P . 0.2). Serum hepcidin did not differ between those with vs. without ascites and with vs. without hepatomegaly (P . 0.10). Serum hepcidin was lower in those with peripheral oedema [9.5 (3.6 -40.7) ng/mL] when compared with those without peripheral oedema [25.0 (10.1-67.5) ng/mL, P ¼ 0.009].
In a multivariable model, the following variables remained statistically significantly associated with the higher prevalence of ID (defined as above) in patients with AHF: higher NT-proBNP and uric acid, lower haemoglobin, and the presence of peripheral oedema (all P , 0.05, Table 1 ).
Indices of iron status and survival in patients with acute heart failure
The mean duration of follow-up in all 165 patients with AHF was 323 + 94 days (median: 365 days); time to death was 158 + 101 days (median: 167 days). In the whole group, the 12-month survival rate was 80.0% (95% CI: 73.9-86.1%) [33 deaths: 30 HF-related deaths and 3 non-cardiovascular deaths (all cancers)].
Univariable analyses
In univariate Cox proportional hazard regression models, the following clinical variables were associated with higher mortality during the 12-month follow-up in patients with AHF: older age, lower systolic BP, the presence of peripheral oedema, the history of previous HF, the presence of cancer, CKD, higher NT-proBNP, urea, AST, bilirubin, uric acid, and IL-6, lower sodium, GFR, albumins and haemoglobin, and the presence of anaemia (all P , 0.05, Table 3) .
In univariate models, low hepcidin and high sTfR (both analysed as continuous and dichotomized variables) as well as low ferritin were associated with higher 12-month mortality rates in patients with AHF (all P , 0.05, Table 3 ).
In patients with AHF, AUC calculated for both serum hepcidin and serum sTfR as combined predictors of death at 12 months was 0.788 + 0.034, which was significantly higher than an analogous AUC for serum sTfR-0.655 + 0.019 (P ¼ 0.02, the most accurate cut-off value 2.56 mg/L) and borderline higher than an analogous AUC for serum hepcidin-0.780 + 0.039 (P ¼ 0.12, the most accurate cut-off value not possible to be estimated), which demonstrated the additive predictive value of these two parameters.
Patients with AHF and ID (low-serum hepcidin and high-serum sTfR) had significantly higher 12-month mortality when compared with those without ID (P , 0.001, Table 3 ). There were three in-hospital deaths; all occurred in patients with low hepcidin (0.09, 1.63, and 7.84 ng/mL) and high sTfR (2.78, 3.18, and 6.18 mg/L). Patients with AHF and ID defined based on serum ferritin and Tsat had only borderline higher 12-month mortality when compared with those without ID (P ¼ 0.06, Table 3 and Supplementary material online, Figure) .
Patients with AHF were divided into four groups based on the combination of low/preserved hepcidin or/and high/preserved sTfR. These four groups differed regarding 12-month mortality rates (Figure 1 ). 
Multivariable analyses
Both low hepcidin and high sTfR (when analysed as both continuous and dichotomized variables) predicted higher 12-month mortality rates in patients with AHF, also after adjustment for all variables which appeared to be significant predictors in univariable models (all P , 0.05, Supplementary material online, Table S1 -selected most important models 
Discussion
In our study, we have demonstrated that patients admitted due to AHF commonly demonstrate profound ID characterized by depleted body iron stores accompanied by uncompromised metabolic needs for iron in target tissues, which is associated with high mortality rates. On the contrary, patients with AHF with preserved iron status have a remarkably good outcome with virtually no deaths during the 12-month follow-up. Our paper extends knowledge on the magnitude of ID and clinical consequences also for those who develop an episode of AHF. Previously, we and others have shown that ID is common in patients with stable HF (including those with and without impaired left ventricular function) and has serious negative clinical and prognostic consequences. 6 -9 Importantly, the pharmacological intravenous correction of ID has brought clinical benefits. 22 -24 Now, we are the first who have provided the evidence on iron status in patients with AHF, and have related it with survival. The previous history of HF (always confirmed on the basis of careful clinical evaluation) was associated with the prevalence of ID defined as low hepcidin and high sTfR, which may extend our previous observations on abnormal iron status in chronic HF. 6, 8 On the other hand, we found ID as a predictor of increased mortality in AHF patients, regardless of the previous history of HF, high NT-proBNP and LVEF, demonstrating that depleted iron had a strong and independent impact of survival in these patients, beyond their cardiovascular status characterized as above. The traditional definition of ID based on low-circulating ferritin and Tsat 15, 16 has been recently applied to patients with various cardiovascular disorders, 4 -9 however, these parameters may be misleading in acute clinical setting. Iron deficiency was defined as serum hepcidin ,14.5 ng/mL and serum sTfR ≥1.59 mg/L. c Iron deficiency was defined as serum ferritin ,100 mg/L, or serum ferritin 100 -299 mg/L with Tsat ,20%. *P , 0.05. **P , 0.01. ***P , 0.001. FAIR-HF trial did not predict the poor outcome. Although AHF is associated with inflammatory activation, so far direct links between inflammation and iron status in patients with AHF have not been established, and the interpretation of levels of circulating ferritin remains unclear.
Taking all the limitations into consideration, we have prospectively focused on the complementary and specific information derived from low-circulating hepcidin (reflecting depleted iron stores) and high-circulating sTfR (reflecting unmet cellular needs for iron). Importantly, we used outermost cut-off points for defining of low-serum hepcidin and high-serum sTfR (the 5th and the 95th percentiles of reference values from age-and gender-matched healthy controls, respectively). Even though, the prevalence of depleted stored iron (low-serum hepcidin) and depleted utilized iron (highserum sTfR) was very common (46 and 66%) in these patients. We want to emphasize that we found very low levels of circulating hepcidin in almost half of patients with AHF, which was not accompanied by anaemia, inflammation, or impaired liver function. Also, high sTfR levels were found in both anaemic and non-anaemic patients with AHF, without any link to inflammatory status. High sTfR in anaemic subjects allows to identify ID-related anaemia with the erythron as the major source of circulating sTfR. However, high sTfR in those with normal haemoglobin level suggests a substantial extra-haematopoietic origin of circulating sTfR and unmet iron needs within non-haematopoietic cells. Most importantly, ID diagnosed as both low-serum hepcidin and high sTfR allowed to identify those with the poor outcome separately in anaemic and non-anaemic subjects, indicating the detrimental effects of depleted iron, also when erythropoiesis was preserved. The magnitude of iron depletion found in AHF also indicates the permanent (long-lasting) nature of this pathology, which seems to be difficult to be quickly and efficiently repleted through only an increase of dietary iron amount. Our data go in accordance with recent evidence indicating reduced iron content in failing human myocardium. 29 -31 Based on the combined assessment of serum hepcidin and serum sTfR, we were able to identify four groups of patients with AHF varying in iron status. The most profound ID was diagnosed based on concomitant low hepcidin and high sTfR. Patients with isolated low hepcidin with preserved (not high) serum sTfR also have depleted iron stores, but metabolic needs for iron are still met, however, may be borderline sufficient, and probably may later develop the full ID. Patients with preserved (not low) serum hepcidin and high-serum sTfR have preserved body iron stores, but develop impaired iron influx to the cells, which may correspond to the so-called functional ID. Importantly, those with profound ID (depleted pools of both stored and utilized iron) have particularly high 12-month mortality, and those who have preserved iron status assessed using these two parameters have the best outcome (no death during 12 months). The two remaining aforementioned groups are also negatively affected in the context of survival, but to a lesser extent when compared with those with profound ID, and may represent the transient stage leading finally to profound ID. We also need to emphasize here that the detrimental effect of ID on survival was observed in both anaemic and non-anaemic patients with AHF, which constitutes another evidence on the role of optimal iron status beyond erythropoiesis. 23 The observational character of the study needs to be acknowledged, as our study was neither designed to investigate the mechanisms underlying such a profound ID nor to explain the mechanisms responsible for detrimental effect of ID on clinical outcomes in these patients. One hypothetical explanation might be links between optimal iron status and mitochondrial functioning, optimal Figure 1 Kaplan-Meier curves demonstrating 12-month survival rates of patients with acute heart failure divided according to iron status defined based on serum hepcidin and serum soluble transferrin receptor.
Iron deficiency in acute heart failure energy metabolism, and protection from oxidative stress. 2,32 -34 There is a clear U-shaped relationship between the amount of mitochondrial iron and its energetic efficacy; both depleted and excessive iron states lead to mitochondrial dysfunction. 32 Iron deficiency in rats causes mitochondrial structural and functional abnormalities in the myocardium accompanied by myocardial hypertrophy and dilatation. 33 Indeed, the myocardium is characterized by extraordinarily high-energy demand, and an intact energy metabolism is crucial for its optimal functioning. Despite neurohormonal and inflammatory activation, the core feature of HF syndrome is abnormal energy metabolism and metabolic myocardial remodelling. 10, 11 An episode of AHF is a clinical entity, where the maintenance of energetic homoeostasis is of a greatest importance, not only from the perspective of failing myocardium, but also other organs which are critical to struggle with decompensation (kidneys, liver, and skeletal muscles).
Patients with AHF and ID had high-circulating uric acid, which being a measure of increased oxidative stress 35 may be the consequence of an overproduction of reactive oxidative species by dysfunctional mitochondria. Iron deficiency was also more common in patients with AHF and concomitant diabetes, another clinical entity associated with abnormal energy metabolism. 36 Links between diabetes and ID have been established, and this interaction has negative impact on cardiovascular outcomes. 5 Further mechanistic studies are needed to address underlying pathophysiological mechanisms linking iron status with the natural history of HF, in particular the episodes of AHF. Our population comprised relatively younger patients (a mean age of 65 years), predominantly men with ischaemic heart disease and reduced LVEF, which truly reflects clinical characteristics of AHF patients referred to a tertiary cardiology centre in our region. Thus, we acknowledge that the results may not be fully generalizable to another cohort of patients typically hospitalized due to HF decompensation. Although 12-month mortality rate of 20% reported in our study may be considered relatively low, it was similar to recently reported by the other European authors. 37, 38 We acknowledge a relatively small number of patients with AHF and a limited number of events as the limitation of our study. It would be desirable to validate our findings in a larger cohort of patients with AHF, who experienced more events in order to perform more comprehensive multivariable survival analyses.
In conclusion, profound ID confirmed as both depleted iron stores and iron avidity of metabolizing cells is common in patients with AHF, and allows to identify those with a particularly poor outcome. Its correction with iron supplementation may be an attractive therapeutic option targeting abnormal metabolism to reduce still unacceptably high mortality in patients with AHF.
